Loading…
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $643M | $4M | $-44M | $130M | -5.5% | 5.2% | - |
| 2024 | $611M | $-134M | $-183M | $-7M | -25.7% | -1.3% | - |
| 2023 | $619M | $-205M | $-255M | $-65M | -34.4% | 19.8% | - |
| 2022 | $516M | $-128M | $-166M | $-165M | -20.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 516.41 | 618.73 | 610.78 | 642.82 |
| Cost Of Revenue | 120.39 | 209.41 | 196.30 | 198.94 |
| Gross Profit | 396.02 | 409.31 | 414.48 | 443.88 |
| Operating Expense | 563.97 | 613.66 | 609.04 | 554.77 |
| Operating Income | -167.94 | -204.35 | -194.56 | -110.89 |
| EBITDA | -128.49 | -205.11 | -133.99 | 3.91 |
| EBIT | -161.50 | -248.73 | -177.70 | -39.91 |
| Pretax Income | -161.97 | -248.76 | -177.70 | -39.91 |
| Tax Provision | 4.03 | 6.34 | 4.93 | 3.64 |
| Net Income | -166 | -255.10 | -182.63 | -43.54 |
| Net Income Common Stockholders | -166 | -255.10 | -182.63 | -43.54 |
| Total Expenses | 684.35 | 823.08 | 805.34 | 753.71 |
| Interest Expense | 0.48 | 0.03 | 0 | 0 |
| Interest Income | 6.65 | 16.89 | 18.93 | 20.05 |
| Research And Development | 265.67 | 270.33 | 264.70 | 238.63 |
| Selling General And Administration | 298.30 | 343.33 | 344.34 | 316.13 |
| Normalized EBITDA | -128.49 | -144.13 | -133.99 | -45.99 |
| Normalized Income | -166 | -206.92 | -182.63 | -82.97 |
| Basic EPS | -1.46 | -2.18 | -1.52 | -0.35 |
| Diluted EPS | -1.46 | -2.18 | -1.52 | -0.35 |
| Tax Effect Of Unusual Items | 0 | -12.81 | 0 | 10.48 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | 0 | -60.98 | 0 | 49.90 |
| Total Unusual Items Excluding Goodwill | 0 | -60.98 | 0 | 49.90 |
| Net Income From Continuing Operation Net Minority Interest | -166 | -255.10 | -182.63 | -43.54 |
| Reconciled Depreciation | 33.01 | 43.62 | 43.71 | 43.82 |
| Reconciled Cost Of Revenue | 120.39 | 209.41 | 196.30 | 198.94 |
| Net Interest Income | 6.17 | 16.85 | 18.93 | 20.05 |
| Net Income From Continuing And Discontinued Operation | -166 | -255.10 | -182.63 | -43.54 |
| Total Operating Income As Reported | -167.94 | -265.33 | -194.56 | -60.98 |
| Diluted Average Shares | 113.86 | 117.17 | 120.45 | 124.75 |
| Basic Average Shares | 113.86 | 117.17 | 120.45 | 124.75 |
| Diluted NI Availto Com Stockholders | -166 | -255.10 | -182.63 | -43.54 |
| Net Income Including Noncontrolling Interests | -166 | -255.10 | -182.63 | -43.54 |
| Net Income Continuous Operations | -166 | -255.10 | -182.63 | -43.54 |
| Other Income Expense | -0.20 | -61.27 | -2.07 | 50.93 |
| Other Non Operating Income Expenses | -0.20 | -0.29 | -2.07 | 1.03 |
| Special Income Charges | 0 | -60.98 | 0 | 49.90 |
| Other Special Charges | 0 | 60.98 | 0 | -49.90 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 6.17 | 16.85 | 18.93 | 20.05 |
| Interest Expense Non Operating | 0.48 | 0.03 | 0 | 0 |
| Interest Income Non Operating | 6.65 | 16.89 | 18.93 | 20.05 |
| Operating Revenue | 516.41 | 618.73 | 610.78 | 642.82 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| 10x Genomics, Inc.this co. | TXG | - | - | - | -5.5% | - |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - | 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |